Unveiling the Generic: What is another name for Tukysa?
•
2 min read
Tukysa, a targeted therapy approved by the FDA in 2020 for certain HER2-positive cancers, is more formally known by its generic name, tucatinib. This oral medication works as a kinase inhibitor to block signaling pathways that promote cancer cell growth, and it is crucial for patients and clinicians to understand its multiple identifiers for accurate treatment management.
